mTOR inhibitor — among the most studied longevity compounds. Extends lifespan in every model organism tested including mice. Human longevity trials ongoing (PEARL trial, Participatory Evaluation of Aging with Rapamycin). Immune-suppression drug repurposed for aging research.
57–63 hours in healthy adults; allows once-weekly intermittent dosing in longevity protocols
SKUs
2
Evidence
Moderate Evidence
Rapamycin (sirolimus) is an FDA-approved immunosuppressant medication that has become one of the most studied compounds in longevity research. It inhibits a cellular signaling hub called mTOR, which regulates cell growth, metabolism, and aging-related processes. It is one of the only compounds shown to extend lifespan in aged mice, which has generated substantial scientific interest in its anti-aging potential.
Longevity and mTOR Research
The landmark ITP (Interventions Testing Program) study found that rapamycin given to mice at 20 months of age (equivalent to about 60 years in humans) extended median and maximum lifespan significantly. This was a major finding because it suggested aging interventions could work even when started later in life.
Immunology and Transplant Medicine
Rapamycin is FDA-approved as an immunosuppressant to prevent organ rejection following kidney transplant. It inhibits T-cell proliferation and is a well-characterized medication in clinical transplant medicine.
Cardiac and Vascular Research
Rapamycin-eluting stents are used in cardiology to prevent restenosis (re-narrowing) of coronary arteries after stenting. This application takes advantage of its cell-growth inhibiting properties locally in the vessel wall.
Intermittent Dosing Longevity Research
Current longevity research interest focuses on intermittent or low-dose rapamycin protocols, based on the hypothesis that periodic mTOR inhibition produces longevity benefits while avoiding the immune suppression of continuous clinical dosing. Human trials of this approach are now underway.
Extended lifespan in multiple mouse studies, including when started in aged animals.
FDA-approved with a well-characterized clinical profile in transplant medicine.
Used in rapamycin-eluting stents to prevent arterial restenosis.
Early human trials of intermittent dosing for aging are underway, with some showing immune function improvements.
Continuous use at immunosuppressive doses carries significant risks including infection and metabolic effects.
Rapamycin is a potent immunosuppressant at doses used in transplant medicine. Continuous use at these doses impairs immune function, increases infection risk, and has metabolic effects including glucose intolerance. Whether intermittent low-dose protocols produce longevity benefits in humans without these risks has not been established. It is a prescription medication. Self-use outside medical supervision carries meaningful risks.
mTOR (mechanistic target of rapamycin) is a signaling protein that acts as a central hub for cell growth decisions. When nutrients and growth signals are abundant, mTOR is highly active, telling cells to grow and divide. Researchers have found that chronically high mTOR activity is associated with accelerated cellular aging — it drives cells to keep growing when they should be slowing down and performing maintenance. Rapamycin binds to a protein called FKBP12, and this complex then blocks mTOR. With mTOR inhibited, cells shift from a growth mode into a maintenance and repair mode. It also activates a cellular cleanup process called autophagy — where cells recycle damaged components. Researchers think these shifts toward maintenance and away from continuous growth mimic some of the anti-aging effects of caloric restriction.
FDA-approved with extensive clinical data in transplant patients. At immunosuppressive doses, serious risks include increased infection susceptibility, impaired wound healing, mouth sores, and metabolic effects including elevated blood glucose and cholesterol. At lower intermittent doses being studied for longevity, the risk profile is expected to be more favorable, but this has not been fully characterized in human trials. It is a prescription medication and use outside of medical supervision is not appropriate.
Moderate Evidence
This compound has been studied in Phase 1 or Phase 2 human trials. Evidence is encouraging but more large-scale trials are needed.
Published Research Ranges
1–6mg/week intermittent in longevity research context (off-label); higher doses in transplant medicine
Research Context Only: These are ranges reported in published scientific studies for educational reference. They are not dosing recommendations. This is not medical advice. Always consult a qualified healthcare professional.
Sources listed here are from the platform research library. All links open the original publication. No citations are generated by AI.
Rapamycin Fed Late in Life Extends Lifespan in Genetically Heterogeneous Mice
A randomized control trial to establish the feasibility and safety of rapamycin treatment in an older human cohort: Immunological, physical performance, and cognitive effects
Research Education Only: This profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions.
We use cookies to enhance your research experience and analyze platform usage. By continuing, you agree to our Cookie Policy.